Amrize <AMRZ.N>: BofA Global Research cuts to underperform from neutral rating
AMRZ•Related News
Ollie’s Bargain Outlet Q2 net sales miss estimates
OLLI•
CytoSorbents says real-world analysis shows 37% drop in severe bleeding with CytoSorb in urgent CABG patients on ticagrelor
CTSO•
Fuelcell Energy Q3 EPS USD -0.64
FCEL•
GitLab Inc <GTLB.O>: Morgan Stanley Raises Target Price to $57.00 From $30.00
GTLB•
Edible Garden regains Nasdaq $1 minimum bid price compliance
EDBL•